BioXcel Therapeutics Inc. (NASDAQ: BTAI) Stock Information | RedChip

BioXcel Therapeutics Inc. (NASDAQ: BTAI) Listen to this Section


$0.68
-0.0010 ( -0.15% ) 267.4K

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Market Data


Open


$0.68

Previous close


$0.68

Volume


267.4K

Market cap


$27.71M

Day range


$0.67 - $0.72

52 week range


$0.65 - $5.62

Insider Ownership Transactions

Total Amount Purchased: -73,443.00 | $ -49,794.35

Date Type Amount Purchased Purchaser
2024-06-18 Sale -2609.00 Mehta Vimal
2024-06-18 Sale -521.00 Yocca Frank
2024-06-18 Sale -521.00 Steinhart Richard I
2024-06-18 Sale -750.00 Wiley Matthew T.
2024-06-18 Sale -521.00 O'Neill Vincent
2024-06-18 Sale -521.00 Rodriguez Javier
2024-06-11 Sale -17000.00 Votruba Michal
2024-06-11 Sale -17000.00 Laumas Sandeep
2024-06-11 Sale -17000.00 Bray June
2024-06-11 Sale -17000.00 MILLER MICHAEL PATRICK

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 14 Aug 06, 2024
10-q Quarterly Reports 87 Aug 06, 2024
8-k 8K-related 13 Jul 17, 2024
8-k 8K-related 14 Jul 16, 2024
8-k 8K-related 13 Jun 25, 2024
4 Insider transactions 1 Jun 18, 2024
4 Insider transactions 1 Jun 18, 2024
4 Insider transactions 1 Jun 18, 2024
4 Insider transactions 1 Jun 18, 2024
4/a Other 1 Jun 18, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.